- Report
- January 2021
- 97 Pages
Middle East, Africa
From €1450EUR$1,500USD£1,237GBP
- Report
- January 2021
- 88 Pages
North America
From €1450EUR$1,500USD£1,237GBP
- Report
- January 2021
- 101 Pages
Asia Pacific
From €1450EUR$1,500USD£1,237GBP
- Report
- October 2023
- 267 Pages
China
From €3868EUR$4,000USD£3,300GBP
- Report
- October 2023
- 94 Pages
China
From €1740EUR$1,800USD£1,485GBP
- Report
- October 2023
- 123 Pages
China
From €1740EUR$1,800USD£1,485GBP
- Report
- July 2023
- 229 Pages
China
From €3868EUR$4,000USD£3,300GBP
- Report
- March 2024
- 132 Pages
Global
From €919EUR$950USD£784GBP
- Report
- July 2023
- 93 Pages
China
From €1740EUR$1,800USD£1,485GBP
From €125EUR$129USD£106GBP
- Report
- October 2023
- 306 Pages
Global
From €5540EUR$5,730USD£4,727GBP
- Report
- October 2023
- 497 Pages
Global
From €5540EUR$5,730USD£4,727GBP
- Report
- August 2023
- 250 Pages
Global
From €5540EUR$5,730USD£4,727GBP
- Report
- February 2021
- 181 Pages
Europe
From €5964EUR$6,168USD£5,088GBP
- Book
- October 2019
- 720 Pages
The Macrolide Antibiotic market is a segment of the Infectious Diseases Drugs market. Macrolides are a class of antibiotics used to treat a wide range of bacterial infections, including respiratory tract infections, skin infections, and sexually transmitted diseases. Macrolides are generally well-tolerated and have fewer side effects than other antibiotics. They are also effective against drug-resistant bacteria, making them an important tool in the fight against antibiotic resistance. Macrolides are available in both oral and intravenous formulations, and are often used in combination with other antibiotics.
The Macrolide Antibiotic market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, and Novartis. Show Less Read more
